Biotest AG

  • WKN: 522723
  • ISIN: DE0005227235
  • Land: Deutschland

Nachricht vom 17.02.2017 | 13:30

Biotest AG: Proceedings against Biotest AG have been closed

DGAP-News: Biotest AG / Key word(s): Legal Matter

17.02.2017 / 13:30
The issuer is solely responsible for the content of this announcement.


/
PRESS RELEASE

Proceedings against Biotest AG have been closed

Dreieich, 17 February 2017. Biotest AG has agreed with the Frankfurt public prosecution on a mutual termination of the proceedings against the company due to the Russia business.

Besides the tax payment already communicated on 4 November 2016, Biotest has paid a corporate fine in the amount of EUR1.0 million. Thereby proceedings against Biotest are closed. Since a provision for this amount has already been recognised in financial year 2016, the payment has no effect on the result in the 2017 financial year.

The public prosecution has moreover ceased investigation proceedings against several employees of the company.

Proceedings against three managers of Biotest AG, including the CFO, continue. The public prosecution has meanwhile filed charges with the competent court due to breach of trust, bribery and tax evasion. It has not yet been decided whether the charges will be admitted.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de

PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



17.02.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

News im Fokus

IRprint: Nachhaltiger Eindruck durch einen professionellen Ausdruck

Das Team von IRprint bietet für geschäftliche Dokumente einen persönlichen Service mit langjähriger Finanzmarktexpertise – angefangen bei der Erstellung von Textinhalten bis hin zum professionellen Druck sowohl im Digital- als auch Offsetdruckverfahren.

Nutzen Sie unser Knowhow in der Kapitalmarktkommunikation und unsere exklusive Kooperation mit CEWE, Europas Marktführer im Bereich Fotoservice mit herausragender Expertise im kommerziellen Online-Druck. So gelingt Ihnen sowohl inhaltlich als auch optisch ein glänzender Auftritt.

GBC im Fokus

SYGNIS AG will mit Innova-Übernahme Synergieeffekte heben

Die SYGNIS AG plant, mit den aktuellen Kapitalerhöhungen (bis zu 10 Mio. €) den Erwerb der Innova Biosciences Ltd. zu finanzieren, eines Spezialisten aus dem Bereich der Proteinmarkierung. Mit dem Erwerb des profitablen Unternehmens sollen Synergieeffekte gehoben, der Workflow erweitert und darüber hinaus die operativen Kennzahlen verbessert werden. Sowohl im Peer-Group-Vergleich als auch innerhalb eines DCF-Bewertungsmodells stufen wir den Kaufpreis als sehr attraktiv ein.

Aktueller Webcast

Douglas Holding AG

6M Interim Financial Results

24. Mai 2017

Aktuelle Research-Studie

Original-Research: FinTech Group AG (von GBC AG): BUY FinTech Group AG

29. Mai 2017